New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2013
08:03 EDTAFFY, TKPYYAnemia drug had side effects soon after it went on the market, WSJ reports
As the FDA evaluates the anemia drug Omontys, used in kidney dialysis patients, life-threatening reactions to it began appearing within months of when the treatment went on the market, according to a review of regulatory records, reports the Wall Street Journal. The drug, from Affymax Inc. (AFFY) and Takeda Pharmaceutical Co. (TKPYY), was linked to allergic reactions and respiratory distress beginning in August 2012, soon after it went on the U.S. market in late April. Reference Link
News For AFFY;TKPYY From The Last 14 Days
Check below for free stories on AFFY;TKPYY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
12:59 EDTAFFYAffymax to host special shareholder meeting
Subscribe for More Information
September 16, 2014
07:31 EDTTKPYYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 11, 2014
06:49 EDTTKPYYFDA approves weight management drug Contrave
The U.S. Food and Drug Administration yesterday approved Contrave as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use in adults with a body mass index of 30 or greater or adults with a BMI of 27 or greater who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation. The effectiveness of Contrave was evaluated in multiple clinical trials that included approximately 4,500 obese and overweight patients with and without significant weight-related conditions treated for one year. Contrave is distributed by Takeda Pharmaceuticals America (TKPYY) for Orexigen Therapeutics (OREX).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use